Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Nearly half of other service providers started using decentralised trials before pandemic

01 Apr 2021 (Last Updated April 1st, 2021 05:24)

Decentralised trials (DCTs) or virtual trials are those that allow patients to participate in the studies without visiting the clinic site.

Decentralised trials (DCTs) or virtual trials are those that allow patients to participate in the studies without visiting the clinic site.

The use of DCTs soared following the COVID-19 pandemic after lockdowns were imposed and several restrictions were placed on movement.

GlobalData conducted a survey to assess pre-pandemic DCT use by company role.

Nearly half of other service providers started using DCTs before pandemicPre-pandemic Decentralised Trial Use by Company Role

The survey found that nearly half (49%) of other contract service providers started using DCTs before the COVID-19 pandemic. It includes CMOs, bioanalysis, training, consulting, software and digital solution providers for clinical trials.

The adoption rate of virtual trials before coronavirus stood at 42% and 36% for CROs and clinical/ investigator sites, respectively.

The survey also found that only 19% of Pharma/ Biotech and 14% of Government/ Academic Institutes explored DCTs before the pandemic hit the world.

The analysis is based on responses received from the GlobalData Coronavirus Survey -– Pharmaceutical Imports/Exports and Supply Chain,​ fielded between 04 June and 22 June 2020.